Efficacy and safety of tirofiban in treatment of branch atheromatous disease in elderly patients
10.3969/j.issn.1009-0126.2025.05.016
- VernacularTitle:替罗非班治疗老年穿支动脉粥样硬化病患者的有效性和安全性观察
- Author:
Shengqi FU
1
;
Lili ZHU
1
;
Shengjie HU
1
;
Jin ZHANG
1
;
Haoran LI
1
;
Sisen ZHANG
1
Author Information
1. 450003 郑州,河南中医药大学第五临床医学院(郑州人民医院)神经内科
- Publication Type:Journal Article
- Keywords:
tirofiban;
atherosclerosis;
dual anti-platelet therapy;
propensity score
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2025;27(5):616-620
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of tirofiban in the treatment of branch atheromatous disease(BAD)in elderly patients.Methods A retrospective analysis was conducted on 215 elderly BAD patients admitted to our department from June 2021 to June 2023.According to their treatment,they were divided into tirofiban group 1(55 cases)and control group 1(160 ca-ses).Using propensity score matching in a ratio of 1∶1 algorithm for adjustment,the differences in baseline features between the two groups were eliminated,and there were finally 53 cases in the tirofiban group 2 and 53 cases in the control group 2 after matching.The NIHSS scores before treatment and at 24 h and 7 d after treatment were collected.All of them were followed up for 90 d,and modified Rankin scale(mRS)was applied to evaluate the prognosis.Results The tirofiban group 1 had significantly lower NIHSS score at 24 h and 7 d after treatment and shorter length of hospital stay than the control group 1(P＜0.05,P＜0.01),so were in the tirofiban group 2 than the control group[3(1,4)vs 3(2,6),1(0,3)vs 1(1,4),8(6,10)d vs 9(8,11)d,P＜0.05].The proportion of mRS score ≤1 was obviously larger in the tirofiban group 1 than the control group 1(P＜0.01).The tirofiban group 2 obtained notably larger proportions of mRS score≤1 and≤2(71.7％vs 43.4％,P=0.003;79.2％vs 60.4％,P=0.034),and smaller proportion of mRS≥4(5.7％vs 20.8％,P=0.045)when compared with the control group 2.Logistic regression analysis indicated that in the patients without diabetes and those non-smoking,tirofiban was associated with increased good outcomes(OR=0.266,95％CI:0.090-0.788,P=0.017;OR=0.341,95％CI:0.107-0.931,P=0.046).Conclusion Tirofiban may effectively improve the clinical outcomes in the elderly BAD patients.But further randomized controlled trials are needed for verification.
